Scilex Holding (SCLX) Revenue (QoQ) (2022 - 2026)
Scilex Holding (SCLX) Revenue (QoQ) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.69% |
| Dec 31, 2025 | -54.17% |
| Sep 30, 2025 | 6.71% |
| Jun 30, 2025 | 97.92% |
| Mar 31, 2025 | -66.44% |
| Dec 31, 2024 | 3.21% |
| Sep 30, 2024 | -11.81% |
| Jun 30, 2024 | 50.40% |
| Mar 31, 2024 | -19.15% |
| Dec 31, 2023 | 33.06% |
| Sep 30, 2023 | -19.59% |
| Jun 30, 2023 | 18.90% |
| Mar 31, 2023 | -11.22% |
| Dec 31, 2022 | 4.76% |
| Sep 30, 2022 | 43.54% |
| Jun 30, 2022 | 16.35% |